TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

Mesoblast and BMT CTN to Initiate Pivotal Trial of Ryoncil® as Part of First-Line Regimen in Adults with Severe Acute GVHD Refractory to Steroids

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Mesoblast Limited
Mesoblast and BMT CTN to Initiate Pivotal Trial of Ryoncil® as Part of First-Line Regimen in Adults with Severe Acute GVHD Refractory to Steroids

Mesoblast and the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) will collaborate on a pivotal Phase 3 trial of Ryoncil® to treat severe acute graft versus host disease (aGvHD) in adults who are unresponsive to corticosteroids, aiming to improve survival rates.

Insights
AVGO   neutral

Listed as a top holding in the fund, but no specific performance analysis given


MESO   positive

Company is expanding treatment options for a critical medical condition, collaborating with a major clinical trials network, and potentially addressing a significant unmet medical need